Search
Displaying 161–170 of 689 for “retinitis clinical trial”
-
Research News
Investigational LUXTURNA has the potential to be both the first pharmacologic treatment for an inherited retinal disease (IRD) and the first gene therapy for a genetic disease in the United States
First adeno-associated viral (AAV) vector investigational candidate to reach this stage of FDA review
Investigational LUXTURNA clinical program includes up to four years of efficacy data, with observation ongoing
-
Pixium Vision Reports Progress in Development of Two Advanced Bionic Retina Systems
Research NewsBoth approaches show strong, near-term potential for providing meaningful vision to people who are otherwise blind from retinal diseases such as retinitis pigmentosa and age-related macular degeneration (AMD).
-
Leber Congenital Amaurosis Research Advances
Research NewsRecent developments in research on Leber congenital amaurosis.
-
Research News
Funding for the new grants was made possible by Foundation’s strong donor base and philanthropic partners
-
Foundation Fighting Blindness Investing Nearly $6.5 Million in New Grants
Foundation NewsThe newly funded research efforts include several therapies that have strong potential to treat a wide range of inherited retinal diseases.
-
Foundation Invests $5.5 Million in Seven New Translational Research Projects
Research NewsProjects target a variety of conditions including: age-related macular degeneration, Stargardt disease, retinitis pigmentosa, and Usher syndrome type 3A
-
Foundation Hosts Workshop on USH1B Research and Therapy Development
Research NewsEmerging dual-vector gene therapies to address current cargo-size limitations were highlighted during the meeting.
-
Funded Foundation Fighting Blindness Grants and Awards for Fiscal Year 2023 (July 1, 2022–June 30, 2023)
-
Foundation News
The four-year study will inform clinical trial design for emerging USH3 therapies.
-
Beacon Stories
18-year-old Marty Dubecky has a very unique decision to make. There are currently four gene therapy clinical trials for him to choose from to enroll in, which would have been unheard of 15 years ago when he was first diagnosed with XLRP.
